Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Aerovate Therapeutics, Inc. (AVTE) Misses Q2 EPS by 4c
August 15, 2022 7:56 AM EDTAerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q2 EPS of ($0.49), $0.04 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.
... More